Corporate News: Hansa Biopharma AB

Hansa Biopharma AB (HNSA.ST) closed its latest trading session on 21 October 2026 at SEK 37.60, representing a 6.17 % increase over the 24‑hour period that ended at 18:57 Central Europe time. The shares are presently liquidated on major Swedish exchanges and the company’s market capitalization sits at SEK 3.70 billion with an outstanding supply of 101.7 million shares. In the past 24 hours, a total of SEK 11.1 million of shares have changed hands.

Market Context

The 200‑day simple moving average for Hansa Biopharma’s stock is SEK 34.23, underscoring a sustained upward trajectory since the month‑end of September. The stock has climbed 5.58 % since the close of the previous month. Historically, the highest price recorded over the past year was SEK 48.22 on 2 September 2026, while the 52‑week low was SEK 23.52 on 23 April 2026.

Recent Corporate Developments

Idefirix (Implifidase) Presentation at ASN Kidney Week

On 21 October, Hansa Biopharma announced that the follow‑up study of its investigational drug Idefirix (implifidase) has been selected for an oral presentation at ASN Kidney Week in Denver. The presentation is scheduled for 23 October during the High‑Impact Clinical Trials session, a platform reserved for studies of particular clinical interest. Earlier in the month, a late‑breaking abstract from the PAES study of Idefirix was also chosen for oral presentation in the same session. These announcements reinforce the company’s commitment to sharing pivotal data with the international nephrology community and positioning Idefirix as a potential therapeutic for antibody‑mediated rejection.

IND Submission for HNSA‑5487

In addition, Hansa Biopharma disclosed that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its investigational therapy HNSA‑5487, targeted at Guillain‑Barré syndrome (GBS). The filing marks a significant step toward regulatory approval in the United States and expands the therapeutic horizon of the company beyond transplantation.

Comparative Performance of Peer Stocks

  • Cellavision (CEVI.ST): down 1.33 % to SEK 165; market cap SEK 4 billion; P/E 30.6.
  • Itab (ITAB.ST): up 0.25 % to SEK 15.9; market cap SEK 4.1 billion; P/E 20.42.Note: Itab will publish its third‑quarter 2026 interim report on 3 November 2026, with a webcast featuring the president, CEO Björn Borgman, and CFO Andreas Helmersson.
  • Bts (BTS‑B.ST): up 2 % to SEK 232; market cap SEK 4.4 billion; P/E 45.9.
  • Traction‑B (TRAC‑B.ST): flat 0 % at SEK 257; market cap SEK 3.8 billion; P/E 11.34.
  • Implantica‑A (IMPASDB.ST): down 3.69 % to SEK 62.3; market cap SEK 4.3 billion.

About Hansa Biopharma

Hansa Biopharma AB, headquartered in Lund, Sweden, specializes in immunomodulatory enzymes for the treatment and prevention of rare diseases and offers transplant rejection services. The company’s core competencies lie in biotechnology and healthcare, serving a domestic Swedish customer base. Hansa Biopharma is publicly listed on the Stockholm Stock Exchange, and additional information can be found on its website at www.hansamedical.com .